We are live on ! Find out more
ALXO icon

ALX Oncology

86 hedge funds and large institutions have $161M invested in ALX Oncology in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,900% more call options, than puts

Call options by funds: $80K | Put options by funds: $1K

24% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 25

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

1% less funds holding

Funds holding: 87 → 86 (-1)

2.02% less ownership

Funds ownership: 89.39% → 87.37% (-2%)

35% less capital inflows, than outflows

Capital inflows: $12.8M | Capital outflows: $19.9M

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
86
Holders Change
-1
Holders Change %
-1.15%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
31
Reduced
25
Closed
12
Calls
$80​K
Puts
$1​K
Net Calls
+$79​K
Net Calls Change
-⁠$146​K

ALXO Hedge Fund Activity: Q1 2023 in Review

86 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2023, worth a combined $161M — down 61% from $411M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ALXO and 11 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 31 added.

The largest buyer was Braidwell, adding an estimated $7.51M. The largest seller was Logos Global Management, cutting an estimated $6.44M.

  • 86 institutional investors held ALX Oncology (ALXO) as of Q1 2023, down from 87 in Q4 2022.
  • Funds reported $161M of ALX Oncology stock for Q1 2023, down 61% quarter-over-quarter.
  • 11 funds opened new ALX Oncology positions in Q1 2023 and 12 closed out, a net change of -1 holder.
  • The largest ALX Oncology buyer in Q1 2023 was Braidwell, an estimated $7.51M added.
  • The largest ALX Oncology seller in Q1 2023 was Logos Global Management, an estimated $6.44M sold.

Based on aggregated 13F filings for Q1 2023.